Royalty Pharma
RPRX
134 hedge funds and large institutions have $8.19B invested in Royalty Pharma in 2020 Q3 according to their latest regulatory filings, with 50 funds opening new positions, 47 increasing their positions, 18 reducing their positions, and 39 closing their positions.
161% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 18
28% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 39
9% more funds holding
Funds holding: 123 → 134 (+11)
2.5% more ownership
Funds ownership: 41.04% → 43.53% (+2.5%)
9% less capital invested
Capital invested by funds: $8.96B → $8.19B (-$770M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
19% less call options, than puts
Call options by funds: $5.21M | Put options by funds: $6.43M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$136M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$96M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$78.6M |
| 4 |
BlackRock
New York
|
+$72.1M |
| 5 |
State Street
Boston,
Massachusetts
|
+$41.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$67.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$36.7M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$34.5M |
| 4 |
Millennium Management
New York
|
-$29.1M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
-$24.3M |
RPRX Hedge Fund Activity: Q3 2020 in Review
134 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q3 2020, worth a combined $8.19B — down 8.6% from $8.96B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new RPRX positions and 39 closed out — a net gain of 11 holders — while 47 added to existing stakes and 18 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $136M. The largest seller was Norges Bank, cutting an estimated $67.8M.
- 134 institutional investors held Royalty Pharma (RPRX) as of Q3 2020, up from 123 in Q2 2020.
- Funds reported $8.19B of Royalty Pharma stock for Q3 2020, down 8.6% quarter-over-quarter.
- 50 funds opened new Royalty Pharma positions in Q3 2020 and 39 closed out, a net change of +11 holders.
- The largest Royalty Pharma buyer in Q3 2020 was Morgan Stanley, an estimated $136M added.
- The largest Royalty Pharma seller in Q3 2020 was Norges Bank, an estimated $67.8M sold.
Based on aggregated 13F filings for Q3 2020.